Status:

ACTIVE_NOT_RECRUITING

Assess Safety and Efficacy of VAD044 in HHT Patients

Lead Sponsor:

Vaderis Therapeutics AG

Conditions:

Hereditary Hemorrhagic Telangiectasia (HHT)

Eligibility:

All Genders

18+ years

Phase:

PHASE1

PHASE2

Brief Summary

Part I: The purpose of this Phase 1b proof of concept study, randomised, placebo controlled, double blind, multicentre study is to asssess safety and efficacy of 2 doses of VAD044 in adult HHT patient...

Detailed Description

Part I: After being informed about the study and the potential risks, all patients giving written informed consent will undergo a two months screening and observation period to determine eligibility f...

Eligibility Criteria

Inclusion

  • For Part I of the study:
  • Diagnosis of HHT by the Curaçao criteria
  • Several epistaxis/week
  • Anaemia
  • COVID-19 vaccination or positive COVID-19 antibody test
  • Patient has given written informed consent to participate in Part I

Exclusion

  • Type 1 diabetes or uncontrolled type II diabetes (insulin or non-insulin dependent)
  • Active COVID-19 infection
  • active uncontrolled infection or known to be serologically positive for HIV, Hep B, Hep C infection
  • Recent procedures on nasal telangiectases (\<6 weeks)
  • Requiring therapeutic anticoagulation
  • Use of drugs with anti-angiogenic properties in the past 8 weeks
  • laboratory abnormalities
  • Fort Part II of the study:
  • Inclusion Criteria:
  • Completion of Part I of the study
  • All adverse events or serious adverse events occuring during Part I of the study have resolved
  • Patient has given written informed consent to participate in Part II

Key Trial Info

Start Date :

July 18 2022

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 1 2025

Estimated Enrollment :

75 Patients enrolled

Trial Details

Trial ID

NCT05406362

Start Date

July 18 2022

End Date

December 1 2025

Last Update

March 4 2025

Active Locations (7)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (7 locations)

1

Massachusetts General Hospital

Boston, Massachusetts, United States, 02114

2

Universitair Ziekenhuis Gent

Ghent, Belgium

3

Hospices Civils de Lyon

Lyon, France

4

Ospedale Maggiore di Crema

Crema, Italy